11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 06.08.2026 Expectation: 800 pips
Selling S&P 500 Index with 7,250 target amid rising bearish pressure
Today at 11:31 AM 29
Period: 31.08.2026 Expectation: 1500 pips
EURUSD sell-off targets 1.1300
Today at 11:14 AM 33
Brent neutral
Period: 31.08.2026 Expectation: 250 pips
Go long on Brent crude with $95 in sight
Today at 11:14 AM 27
Period: 30.08.2026 Expectation: 1500 pips
Invest in USDJPY up to 165.00
Today at 09:33 AM 19
Gold buy
Period: 06.08.2026 Expectation: 160 pips
Invest in gold as Fed keeps rates unchanged
Today at 08:24 AM 34
Period: 06.08.2026 Expectation: 150 pips
Buy ETHUSD with $2,050 in sight amid steady demand
Today at 07:07 AM 22
Go to forecasts